Transcripta Bio
Biotechnology · Medical AI
$34Mtotal raised · 2 rounds on record
$24Mlatest round · Series A · Jul 2026 · 3 mo ago
1backers · BlueYard Capital
50+team · employees, estimated range
Overview
Drug discovery at the resolution of biology. Using the power of the transcriptome to discover revolutionary medicines.
Funding and backers
Total raised
$34M
2 rounds on record
Latest round
$24M
Series A · Jul 2026 · 3 mo ago
Team
51-200
employees, estimated range
Backers
1
BlueYard Capital
The money's age
Fresh money
3 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 22
Raised a round Series A $24M
May 30, 2025
Partnership Transcripta Bio collaborates with Microsoft Research to Advance AI-Driven Disease-Gene Discovery · medindia.net
Apr 29, 2024
Raised a round Venture round $10M · Pulse 2.0
Apr 2024
Website went live first capture in the Wayback Machine
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Jul 2026 | $24M | — | morningstar.com |
| Venture round | Apr 2024 | $10M | — | Pulse 2.0 |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
backs Stemnovate
backs Gandeeva
Similar startupsby what they do, their industry and backers
Defining a new era in drug discovery where chemistry rewrites the rules of biology to engage any protein target.
Light Horse is a small molecule drug discovery company that is leading the way in a.
Gandeeva Therapeutics is a precision medicine company leveraging cryo-EM and machine learning for drug discovery.
Zymedi leverages ARS biology to discover novel therapeutics and first-in-class drugs for patients.
Enzymlogic is a world leading analytical CRO for drug discovery with expertise in the kinetic profiling of compounds to facilitate drug…
Pioneering next generation therapeutics through cutting-edge research and AI-powered drug discovery.
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
BlueYard CapitalVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Transcripta Bio Announces Scientific Advisory Board to Advance High-Certainty Drug Discovery
PALO ALTO, Calif., September 23, 2026--Transcripta Bio, an AI-powered drug discovery company focused on neurological and neuromuscular diseases, today announced additions to its Scientific Advisory Board (SAB). The SAB includes leaders with expertise in h
Read more
Report
Transcripta Bio Raises $24 Million To Advance AI-Powered Neurological Drug Pipeline
Transcripta Bio has raised $24 million since its Series A financing to advance an AI-powered drug discovery platform focused on neurological and neuromuscular diseases. New investors Mayo Clinic and Omnimed joined existing backers JAZZ Venture Partners, B
Read more
Report
Transcripta Bio Announces $24 Million in Funding to Advance AI-Powered Drug Discovery Platform for Neurological and Neuromuscular Diseases
PALO ALTO, Calif., July 22, 2026--Transcripta Bio, an AI-powered drug discovery company focused on neurological and neuromuscular diseases, today announced it has raised $24 million since its Series A to advance IND-enabling studies across its portfolio a
Read more
Report
Transcripta Bio Announces $24 Million in Funding to Advance AI-Powered Drug Discovery Platform for Neurological and Neuromuscular Diseases
Read more
Report
High-throughput transcriptomic screening reveals entrectinib as a repositioning opportunity in 19q12 autism spectrum disorder
Discovering new and viable therapies for genetic diseases is a time-consuming and cost-intensive process, especially for rare disorders. In this study, we highlight how a high-throughput drug discovery platform was utilized to uncover drugs at scale that
Read more
Report
Transcripta Bio collaborates with Microsoft Research to Advance AI-Driven Disease-Gene Discovery
Read more
Report
TIME100 Most Influential Companies 2024: Transcripta Bio
Transcripta Bio: 2024 TIME100 Most Influential Companies
Read more
Report
Transcripta Bio: $10 Million Raised To Speed Up Drug Discovery With Lower Risk
Transcripta Bio, a company focused on drug discovery at unprecedented speed and scale, with lower risk and higher certainty across multiple diseases in parallel, announced its launch with $10 million in funding.
Read more
Report